Rectal Adenocarcinoma
Conditions
Brief summary
Phase II Study of Neo-adjuvant Chemoradiotherapy using infusional Gemcitabine followed by Surgery for Locally Advanced (T3 and T4 or Node positive) Rectal Adenocarcinoma.
Detailed description
Results of neo-adjuvant chemo-radiation for advanced rectal cancer have plateaued with pathological complete response rates of 10-20% in spite of the addition of new cytotoxic agents and/ or molecular targeted therapies. The combination of 5-fluorouracil and radiation produces effective sensitization but further improvements require assessment of other sensitizers to increase the pathological complete response rates. Gemcitabine has been used in combination with radiation for several GI cancers but few studies have examined its role in rectal cancer. This study will examine a combination of Gemcitabine and radiation as neo-adjuvant therapy in advanced rectal cancer to increase the pathological complete response (pCR) rate from the investigators traditional 6% to \> 40 %.
Interventions
DRUGGemcitabine
Nucleoside analog- Chemotherapy
RADIATIONXRT
pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
DRUGcapecitabine
Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
Sponsors
King Faisal Specialist Hospital & Research Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Adenocarcinoma of the rectum without evidence of distant metastases 2. Patient must be 18 years of age or greater 3. Potentially resectable disease based upon surgeons evaluation 4. Clinical stages T3 or T4a, and/ or positive nodes based upon endorectal ultrasound and/ or MRI. 5. Absolute neutrophil count of \> 1500 per microliter and platelet count \> 100,000 per microliter; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and alkaline phosphatase \< 2.5 X upper limit of normal (ULN), bilirubin \< = 1.5 ULN, calculated creatinine clearance \> 50 ml/min using Cockcroft-Gault formula: Male: Creatinine Clearance = (140 - age) x weight/(72 X serum creatinine) Female: Creatinine Clearance = (140 - age) x weight/(72 X serum creatinine x 0.85) 6. Eastern cooperative oncology group (ECOG) performance status 0-2 7. No history of other malignancies within 5 years, except non-melanoma skin cancer, in situ carcinoma of the cervix, or ductal carcinoma in situ of the breast. Previous invasive cancer permitted if disease free at least 5 years. 8. Signed study-specific informed consent prior to enrolment
Exclusion criteria
1. Any evidence of distant metastasis 2. Synchronous primary colon carcinomas, except T1 lesions (full colonoscopy not required for enrollment) 3. Extension of malignant disease to the anal canal 4. Prior radiation therapy to the pelvis 5. Prior chemotherapy for malignancies 6. Pregnancy or lactation, (exclusion due to potential adverse effects of therapy). Women of childbearing potential with either a positive or no pregnancy test (serum or urine) at baseline. Women/men of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered to be of non-childbearing potential.) Patients will agree to continue contraception for 30 days from the date of the last study drug administration. 7. Serious, uncontrolled, concurrent infection(s). 8. Participation in any investigational drug study within 4 weeks preceding the start of study treatment 9. Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months. 10. Evidence of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake 11. Other serious uncontrolled medical conditions that the investigator feels might compromise study participation. 12. Major surgery within 4 weeks of the study treatment 13. Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome 14. Known, existing uncontrolled coagulopathy 15. No concurrent cimetidine allowed
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Estimate the rate of pathological complete response following neoadjuvant combined-modality therapy using weekly Gemcitabine and radiation therapy in rectal cancer. | 3 years | PCR will be assessed during the course of study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Estimate the incidence of hematologic and non-hematologic grade 3-4 toxicity with the above regimen | 3 years | Toxicity will be evaluated for 3 years and beyond |
| Predictive value of positron Emission Tomography (PET) scan | within 2 month of finishing pre-operative chemoradiotherapy | To assess the positive predictive value and negative predictive value of positive PET and negative PET for pathological complete response. In addition we will correlate the decrease of SUVmax by 50% with survival in patient treated with neo-adjuvant radiotherapy and Gemcitabine in for locally advanced rectal cancer |
| R0 resection rate | at the time of surgery ( 2.5 months) from completion of pre-operative chemoradiotherapy | To assess the adequacy of R0 resection for tumors following down staging using the pre-operative concurrent chemoradiotherapy with Gemcitabine. |
Countries
Saudi Arabia
Contacts
Primary ContactShouki Bazarbashi, MD
Backup ContactFazal Hussain, MD
Outcome results
None listed